<DOC>
	<DOC>NCT02769494</DOC>
	<brief_summary>This study aims at evaluating efficacy and safety of topical using Mesalazine Sustained-Release Tablets in in the treatment of oral ulcers in patients with Crohn's disease.</brief_summary>
	<brief_title>The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer</brief_title>
	<detailed_description>The study will include three phases: screening, treatment and follow-up. Screening: This phase will last a maximum of 7 days and subjects eligibility will be evaluated after informed consent signature. Treatment: Subjects are randomly assigned to treatment and will be treated for 7 days. Daily oral ulcer area and symptoms were recorded during the treatment period. A randomization visit will take place on day 0 and an end-of-treatment visit will take place between day 6 and 8. Follow-up: 28 days after the end of treatment. Efficacy of treatment was evaluated by the oral ulcer remission or decreasing.</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Oral Ulcer</mesh_term>
	<mesh_term>Riboflavin</mesh_term>
	<mesh_term>Flavin Mononucleotide</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Age between 18~65, both gender. Patients with oral ulcer and confirmed Crohn's disease. Contraindications to study drugs. Underwent or will accept oral Surgery. Patients are not able to sign the informed consent or not comply with the study protocol. Planning for pregnancy, pregnancy and lactating women. Enrolled in other clinical trials in the past 30 days. Patients with concurrent / new other serious diseases will affect the effectiveness and safety evaluation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Oral ulcer</keyword>
	<keyword>Crohn's disease</keyword>
</DOC>